Molecular sequelae of proteasome inhibition in human multiple myeloma cells - Wikidata - wikimedia - TriplyDB

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

http://www.wikidata.org/entity/Q34393832

about

Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma Human Fas-associated factor 1, interacting with ubiquitinated proteins and valosin-containing protein, is involved in the ubiquitin-proteasome pathway Inhibition of macroautophagy triggers apoptosis Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death Ganetespib: research and clinical development Advances in the understanding of mechanisms and therapeutic use of bortezomib New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of action Development of Novel Immunotherapies for Multiple Myeloma Proteasome inhibitors disrupt the unfolded protein response in myeloma cells Aspirin induces apoptosis through the inhibition of proteasome function BET bromodomain inhibition as a therapeutic strategy to target c-Myc Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice NF-kappaB and IKK as therapeutic targets in cancer Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication.A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma Targeting the UPS as therapy in multiple myeloma.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo.Apoptosis of multiple myeloma.Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition?Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.

P2860

Q24202358-34F0092B-DBA5-4618-AAB8-C104E4D098D2 Q24297296-A389A7AF-3CBD-4DE1-BFFA-C1EA9B782661 Q24338482-CE42F7C7-6401-4ED3-984F-1C68E6122A01 Q24669763-35FBF0FC-83C6-4EC1-8A20-500D3545C090 Q24670297-426F1BC5-EB5D-420C-A2B1-38FEDCBE74BC Q24679412-D4D82738-48DC-4841-B689-C6B73F7571FC Q26738549-86950E18-296D-41F3-8F19-C5EA75E64D2E Q26798645-7AA66F81-1A57-4B03-92DD-00BF36C5058C Q26849940-E55CE887-1D07-4CEC-BC82-1AB748818265 Q27004421-18D6462C-AE9E-4742-B5C4-A11E7EBB0F54 Q27692033-96180F5C-3101-476A-8994-12314D62A1E5 Q27930325-A4AE5CA9-0AB8-4D75-BD94-9B669A88836A Q28066890-4803C586-A79B-4CDA-AF5A-801DC1E15818 Q28155919-5EEA808E-E7D1-487F-A901-100D6283E816 Q28199915-8B3BC453-515F-4E60-9A0E-9F4FEFA03AC6 Q28247024-5A7FAB47-0AE9-4B8C-957B-167C4DAF371F Q28279454-067C2C50-748F-45D3-81D5-F7616AE2BC91 Q28291312-4914F288-B605-4258-AAFD-C3A103C006A5 Q28297985-5F9E8FF7-C390-440C-A656-8552E4107ADE Q28485441-63A61E6F-E245-42A7-A3C9-76BB5C14E58B Q33326624-E857BBB9-F855-43C4-B82D-52D0305B8545 Q33367833-604BACED-84B8-4014-A18C-AB8325CBEEC9 Q33384287-F4B3EC41-2E27-4F98-B2DB-0DEF64C15BB1 Q33389111-BFF0FBF5-1246-47BF-A8C6-D2FB6F77BFAF Q33390600-9730ECD4-1588-4B5C-B5F9-1E1593535060 Q33394873-3E2CE9AF-5D0D-466F-908C-0801C9A4ED8C Q33399844-A28E1AD3-5435-4626-89A3-32987E1D0283 Q33405532-C7ADDB6D-4770-4350-A6F4-34A23B760620 Q33429980-F12AC850-3DAA-4DBA-9D26-359AB36E1799 Q33443555-02307305-AF81-44F4-BD5D-7A97624D6CC8 Q33627051-A7610F4A-E1E4-4402-8C7C-3B4CD4508117 Q33702365-52239B9C-528D-439C-9BAF-CBA7F623ABDC Q33712077-FBA0F0E8-39F8-4405-830D-17A1EA15DDE3 Q33854012-0906572F-0029-4A69-B65B-97CDBB1847D7 Q33899708-AA8DB4E1-4CD8-402C-AFFE-C88195F255A9 Q33906748-021D9556-7557-43D6-AF42-599C66828CBB Q33930178-3737A6DF-4AFE-4BD5-8660-36539E41CF0B Q34022979-6E933131-EF0C-4D92-AFBC-54B79E7381EB Q34082489-7AA61E5F-21A7-4D7E-A34D-79851EC332A8 Q34127846-3A98F9E1-773A-41C4-B212-A9317F740458

P2860

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

http://www.wikidata.org/entity/Q34393832

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@ast

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@en

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@nl

type

label

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@ast

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@en

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@nl

prefLabel

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@ast

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@en

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@nl

P1433

Q34393832-7AA7BBC2-05C9-4346-B36C-88996E0CB9A9

P1476

Q34393832-8C1E6C51-BAE0-45B0-B860-D38076919D44

P2093

Q34393832-13278886-6EAD-4277-A663-6CC7791C88C6

Q34393832-27DD50BE-F2C3-46D1-84F5-30DBDFF42E27

Q34393832-397BCEBE-8288-4308-8373-8F4002771611

Q34393832-563E6581-CA89-4AAE-A9B2-8CA5C14036E3

Q34393832-5EAE0D15-DA10-4046-AC9B-2C7840AF8406

Q34393832-5F89968A-00B9-437D-A310-2D5C17AB03EE

Q34393832-63A4D3AE-FA77-4A4A-ABED-9520D4ABD45D

Q34393832-886B79BE-4DEC-473F-AAD2-F88D05634053

Q34393832-912B2B31-3A89-4E8F-81FF-1AEE5D9F1E46

Q34393832-DD099A26-B129-4FEC-95DD-0EC2759D3E62

P2860

Q34393832-0170FAD8-735C-462D-824E-BD75A589FC81

Q34393832-09390403-F43F-4692-9BF6-191029176B5C

Q34393832-09F5178C-CA48-45AD-A468-827DBD8E3971

Q34393832-0F2C843D-A2E6-4AFE-8BA8-485ABE6C5EDB

Q34393832-27EF12A1-7CEE-45DA-BB8C-9A0C822EB277

Q34393832-2C075375-F072-4F64-A449-9648F42861CF

Q34393832-2C0FBD20-2D12-45D1-B2D4-86738E72D6C3

Q34393832-2D1F6B93-2F41-4DC0-8E6D-57A6204F81ED

Q34393832-318DBC53-D249-483E-B0B4-96ADA7AFA942

Q34393832-3DB5C2C3-B0C3-4D7B-B75B-21A8B541A5CF

P304

Q34393832-F9B2C4BB-2EB0-49A5-854E-F57459D6975D

P31

Q34393832-CB1C6450-93E4-4C28-9162-F378B0BE9B4C

P356

Q34393832-23AD4FCF-302D-4145-B36F-31522B06A581

P407

Q34393832-A231FF60-D9E5-4255-A80B-6E7949CE9B40

P433

Q34393832-1C3F3562-AEE1-46AD-BE02-71A0A5C9168A

P478

Q34393832-B0F28A08-6751-4F7F-81F0-F2476E1CD938

P50

Q34393832-350617AC-F451-4E4C-AA55-EF97C921F0D9

Q34393832-5FF0356F-2A87-4A3F-B5BD-51D272530750

Q34393832-63222600-D444-45AC-81CC-52F2914FE43E

Q34393832-78A10DD0-52EE-473A-B536-F1B46FD797CD

P577

Q34393832-34CF9549-BC29-4C99-9A1C-FBC977E5C514

P5875

Q34393832-F5D1328B-59A0-42C2-9759-24EAF7A870A8

P698

Q34393832-BF31BB19-5324-458C-AF4B-7CA8AEEE87E7

P932

Q34393832-14F4D5E9-C600-46CD-9FB4-EDFEC2068234

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

@en

P2093

Charles Bailey

http://www.w3.org/2001/XMLSchema#string

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Marie Joseph

http://www.w3.org/2001/XMLSchema#string

Nicholas Mitsiades

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Steven P Treon

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

Vassiliki Poulaki

http://www.w3.org/2001/XMLSchema#string

Xuesong Gu

http://www.w3.org/2001/XMLSchema#string

P2860

An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9

Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn negatively regulates genotoxic apoptosis

CDNA cloning of p112, the largest regulatory subunit of the human 26s proteasome, and functional analysis of its yeast homologue, sen3p

Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit

Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade

Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells

cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y

cDNA cloning and functional analysis of the p97 subunit of the 26S proteasome, a polypeptide identical to the type-1 tumor-necrosis-factor-receptor-associated protein-2/55.11

Nin1p, a regulatory subunit of the 26S proteasome, is necessary for activation of Cdc28p kinase of Saccharomyces cerevisiae

cDNA cloning and functional analysis of p44.5 and p55, two regulatory subunits of the 26S proteasome

P304

14374-14379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.202445099

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Galinos Fanourakis

Towia A Libermann

Kenneth C Anderson

Paul G Richardson

P577

2002-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11071624

http://www.w3.org/2001/XMLSchema#string

P698

12391322

http://www.w3.org/2001/XMLSchema#string

P932

137891

http://www.w3.org/2001/XMLSchema#string